Published on 6/13/2006 in the Prospect News Biotech Daily.
Aegerion Pharmaceuticals completes $22.5 million series A round
By Elaine Rigoli
Tampa, Fla., June 13 -Aegerion Pharmaceuticals, Inc. has closed $22.5 million in a series A round of financing led by Advent International, Index Ventures, Alta Partners and MVM Life Science Partners.
The company said the capital will support further development of compounds that have been shown to significantly reduce LDL "bad" cholesterol.
Aegerion Pharmaceuticals is a specialty pharmaceutical company located in Bridgewater, N.J.
| Issuer: | Aegerion Pharmaceuticals, Inc.
|
| Issue: | Series A financing
|
| Amount: | $22.5 million
|
| Investors: | Advent International, Index Ventures, Alta Partners, MVM Life Science Partners
|
| Announcement date: | June 13
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
